Lenz Therapeutics (LENZ) announced the FDA approved Vizz 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October, with commercial product to be broadly available by mid-Q4. Direct-to-eye care professional sales and marketing activities to be initiated immediately.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ: